All Posts By

Motif

Exercise of Options

By Press Releases
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company will issue 53,887 ordinary shares of 1 penny each (“Option Shares”)  in settlement of options that have been exercised by a former director. The options were exercised at a price of US $0.13918 per ordinary share for total consideration of US $7,500. Admission to trading on AIM (“Admission”) of the Option Shares, which will rank pari passu with the existing Ordinary Shares, will be applied for, and it is expected that Admission will become effective and dealings in the new Ordinary Shares will commence on 19 October 2015. Total Voting Rights Following Admission, the total issued share capital of the Company...
Read More

Directors Dealings

By Press Releases
Motif (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics was notified, on 2 October 2015 that Dr. John Stakes, Non Executive Director of Motif, purchased 100,000 ordinary shares in the Company at 60 pence per ordinary share on 2 October 2015. Accordingly, Dr. John Stakes owns 171,850 ordinary shares, representing approximately 0.16 per cent of the Company’s issued share capital. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer info@motifbio.com Zeus Capital Limited (Nominated Advisor and Broker) Phil Walker / John Treacey Dominic Wilson +44 (0) 207 533 7727 Northland Capital Partners (Broker) Patrick Claridge / David Hignell John Howes / Mark Treharne (Broking) +44 (0) 207 382 1100 MC Services AG (Trade PR) Raimund...
Read More

Motif Announces Presentation of Two Posters on Iclaprim at ID Week 2015

By Press Releases
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that data from two iclaprim clinical studies have been accepted for presentation at the Infectious Disease Week 2015 (ID Week) conference in San Diego, California which runs from the 7th to the 11th of October 2015. Iclaprim is a novel antibiotic, targeting the bacterial dihydrofolate reductase enzyme, currently beginning two Phase III studies to treat acute bacterial skin and skin structure infections (ABSSSI). The two posters: “Cessation of Spread of Lesion and Absence of Fever at 72 hours in Complicated Skin and Skin Structure Infection (cSSSI): Reanalysis of the Combined ASSIST Phase III Studies Comparing Iclaprim (ICL) and Linezolid (LZD).” Skin and skin...
Read More

Issue of Shares for Exercised Warrants

By Press Releases
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that the Company has issued 140,321 new Ordinary Shares in settlement of an exercise of warrants.  The exercise price of the warrants was 20 pence.  The new Ordinary Shares represent 0.13% of the enlarged issued share capital. Admission to trading on AIM of the 140,321 new Ordinary Shares, which rank parri passu with the existing Ordinary Shares, is expected on 28 September 2015. Following the allotment, the total issued share capital will increase to 108,486,537 Ordinary Shares with each share holding one voting right. Enquiries Motif Bio plc Graham Lumsden, Chief Executive Officer Robert Bertoldi, Chief Financial Officer info@motifbio.com MC Services AG (TRADE PR) Raimund...
Read More

FDA Grants Fast Track Designation for Iclaprim

By Press Releases
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for iclaprim intravenous (IV) to treat Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Hospital Acquired Bacterial Pneumonia (HABP). The FDA's Fast Track programme is designed to aid the development and accelerate the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Drugs with Fast Track designation typically qualify for priority review, which expedites the FDA review process and market approval. Companies that receive Fast Track designation for a drug benefit from more frequent interactions with the FDA during...
Read More

Motif Appoints Westwicke Partners as Investor Relations Adviser in U.S.

By Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has appointed Westwicke Partners as its investor relations adviser in the U.S. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector. Graham Lumsden, CEO of Motif, said: “We look forward to building a relationship with the Westwicke team and to leveraging their experience as we continue to move our clinical development programs forward”. About Westwicke Partners Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to healthcare companies. With offices in Baltimore, Boston, San Francisco and San Diego, the firm works with over 80 public and...
Read More

Participation at Upcoming Investor Events

By Press Releases
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that management will participate in three upcoming investor events as outlined below. The Rodman & Renshaw Annual Global Investment Conference on September 8 through September 10, 2015 at the St. Regis Hotel in New York. Motif will be presenting at 2:10 pm on September 10 in the Louis XVI A room. BioCentury’s 22nd Annual NewsMakers in the Biotech Industry conference on September 10, 2015 at the New York City Millennium Broadway Hotel & Conference Center. Motif will be presenting at 10:00 am in room 311. Ladenburg Thalmann 1st Annual Healthcare Conference on September 29, 2015 at the Sofitel Hotel in New York. Motif will be presenting at 10:30...
Read More

Interims Results for the Six months to 30 June 2015

By Press Releases
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its maiden interim financial results as an AIM-listed Company. Download the condensed consolidated statement of comprehensive income for the six months ended 30 June 2015 Corporate/operational highlights: On 2 April 2015, the Company completed an AIM listing raising £2.8 million at 20 pence per share; The U.S. Food and Drug Administration (FDA) agreed to Phase III trials of iclaprim; and Motif partnered with a global leading CRO for Phase III clinical trials of iclaprim. Financial Highlights: Cash and cash equivalents as at 30 June 2015 of $2.8 million (31 December 2014: nil) Since Period End: QIDP designation granted by the FDA for iclaprim...
Read More

Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study

By Press Releases
Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the topline results of an independent report from microbiology specialists, JMI Laboratories. The report shows that iclaprim is effective in vitro against a range of Gram-positive bacteria, including Staphylococcus aureus, one of the key causes of acute bacterial skin and skin structure infection (ABSSSI) and hospital-acquired bacterial pneumonia (HABP). The recently completed laboratory study tested iclaprim against more than 2,000 bacterial strains, including 1,178 strains of Staphylococcus aureus collected in 2014 from patients in the U.S.A., Europe, Asia Pacific, and Latin America. Iclaprim was found to be 16-fold more potent than trimethoprim, the only other antibacterial dihydrofolate reductase inhibitor (DHFRi) administered alone in today’s market....
Read More

FDA QIDP Designation for Motif’s Lead Antibiotic Candidate Iclaprim for ABSSSI

By Press Releases
Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the U.S. Food & Drug Administration (FDA) has designated iclaprim, a broad-spectrum antibiotic designed to be effective against multi-drug resistant bacteria, as a Qualified Infectious Diseases Product (QIDP) for acute bacterial skin and skin structure infections (ABSSSI). The Company requested QIDP designation for iclaprim for two serious and life threatening infections, hospital acquired bacterial pneumonia (HABP) and ABSSSI. QIDP designation has already been confirmed for HABP. QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), makes iclaprim eligible for certain incentives, including priority review and fast track designation.  With QIDP designation, iclaprim is now eligible for an additional five-year extension...
Read More